2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3652 Phase 3 study (frontMIND) of tafasitamab and lenalidomide plus R-CHOP vs R-CHOP in patients with previously untreated diffuse large B-cell lymphoma: Clinical characteristics and outcomes by age

John M. Burke, MD, Chan Cheah, MBBS, DMSc2, Umberto Vitolo, MD3, Georg Lenz, MD4, Haifaa Abdulhaq, Clinical Professor5, Marek Trnený, MD, CSc, Prof.6, Christopher P. Fox, MD, PhD7, Annalisa Chiappella, MD8, Thomas Witzig, MD9, Young-Woo Jeon, MD10, Boyu Hu, MD11, Christiane Pott, MD12, Samuel Tassi Yunga, MD, PhD13, Sonia Ioannidis14, Lulu Cheng15, Johannes Duell, MD16
1 Sarah Cannon Research Institute at Rocky Mountain Cancer Centers, Aurora, Colorado, United States
2 Hollywood Private Hospital and University of Western Australia, Nedlands, Western Australia, Australia
3 INOC-Istituto Nazionale Oncologico Candiolo; IRCCS, Candiolo, Turin, Italy
4 University Hospital Münster, Münster, Germany
5 University of California San Francisco, Fresno Campus, Fresno, California, United States
6 First Faculty of Medicine Charles University, Prague, Czech Republic
7 Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, University of Nottingham, Nottingham, United Kingdom
8 Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology, Milan, Italy
9 Mayo Clinic, Rochester, Minnesota, United States
10 Yeouido St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Rep. of South
11 Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States
12 University Hospital Schleswig-Holstein, Kiel, Germany
13 Incyte Corporation, Wilmington, Delaware, United States
14 Incyte Biosciences International Sàrl, Morges, Switzerland
15 Incyte Corporation, Wilmington, Delaware, United States
16 University Hospital Würzburg, Würzburg, Germany

Introduction: The incidence of diffuse large B-cell lymphoma (DLBCL) increases with age, and outcomes worsen in older compared with younger patients (pts). Current regimens have shown inconsistent benefit across age groups. At the primary analysis of frontMIND (NCT04824092), a global, phase 3, double-blind, placebo-controlled study, tafasitamab (Tafa) plus lenalidomide (Len) added to R-CHOP (Tafa-Len-R-CHOP) demonstrated a statistically significant 25% reduction in risk of disease progression or death vs R-CHOP (hazard ratio [HR] 0.75 [95% confidence interval [CI]: 0.59, 0.96]; P=0.0194); benefit was also observed in a prespecified analysis by age (<65 and ≥65 y) (Lenz G et al., Lancet 2026). This post hoc analysis further evaluated clinical outcomes in pts in other specified age subgroups.

Methods: Pts were aged 18-80 y with previously untreated, high-intermediate or high-risk DLBCL or high-grade B-cell lymphoma (International Prognostic Index [IPI] 3-5, age-adjusted IPI [aaIPI] 2-3 if ≤60 y), and ECOG-PS 0-2. Pts were randomized 1:1 to Tafa-Len-R-CHOP or R-CHOP. The primary endpoint was investigator-assessed progression-free survival (PFS). Key secondary endpoints were event-free survival (EFS) and overall survival (OS); other secondary endpoints included objective response rate (ORR) at EOT and safety. Minimal residual disease (MRD) was an exploratory endpoint. Outcomes were assessed in pts aged ≤60 y and >60 y, as well as <70 y and ≥70 y.

Results: Overall, 899 pts were randomized to Tafa-Len-R-CHOP (n=448) or R-CHOP (n=451). Of the total pts enrolled, 34% were aged ≤60 y (Tafa-Len-R-CHOP, n=152; R-CHOP, n=158) and 66% were aged >60 y (Tafa-Len-R-CHOP, n=296; R-CHOP, n=293). Within each age category, baseline characteristics were generally similar between treatment arms; disease burden was high across all age groups (Ann Arbor stage III/IV disease >96%, elevated LDH 82-85%). Mean baseline creatinine clearance was 113.8 mL/min and 82.8 mL/min in pts ≤60 y and >60 y, respectively. All median relative dose intensities (RDIs) across 6 cycles for Tafa and Len were 100% and ≥80% for pts aged ≤60 y, and 99% and ≥60% for pts aged >60 y, respectively. Median RDIs for all R-CHOP components across 6 cycles were 100% in both the Tafa-Len-R-CHOP and R-CHOP arms for pts aged ≤60 y and >60 y, except for vincristine which were ≥92% and 100% for pts ≤60 y and ≥92% and ≥87% for pts >60 y, respectively.

Positive trends in investigator-assessed PFS were observed with Tafa-Len-R-CHOP vs R-CHOP in pts aged ≤60 y (HR 0.63 [95% CI: 0.41, 0.97]) and >60 y (HR 0.83 [95% CI: 0.62, 1.11]). PFS rates at 24 months in pts aged ≤60 y were 76.1% (95% CI: 67.9, 82.5) and 63.7% (95% CI: 55.2, 71.0) for pts in the Tafa-Len-R-CHOP and R-CHOP arms, respectively. For pts aged >60 y, PFS rates at 24 months were 68.5% (95% CI: 62.3, 73.9) and 62.4% (95% CI: 56.0, 68.1) for pts in the Tafa-Len-R-CHOP and R-CHOP arms, respectively. Positive trends were also observed with Tafa-Len-R-CHOP vs R-CHOP for EFS (≤60 y, HR 0.75 [95% CI: 0.52, 1.10]; >60 y, HR 0.81 [95% CI: 0.62, 1.04]) and ORR at EOT (≤60 y, odds ratio [OR] 1.60 [95% CI: 0.89, 2.86]; >60 y, OR 1.22 [95% CI: 0.83, 1.80]). MRD negativity at end of treatment in the Tafa-Len-R-CHOP and R-CHOP arms was 82.4% (95% CI: 73.9, 89.1) and 64.3% (95% CI: 54.7, 73.1) for pts aged ≤60 y and 80.6% (95% CI: 74.4, 85.9) and 68.0% (95% CI: 61.1, 74.3) for pts aged >60 y, respectively. OS data are immature but a trend in favor of Tafa-Len-R-CHOP was observed in both age subgroups (data not shown).

Treatment-emergent adverse events (TEAEs) were reported in ≥97% of pts in the Tafa-Len-R-CHOP and R-CHOP arms across age subgroups. Grade ≥3 TEAEs occurred in the Tafa-Len-R-CHOP and R-CHOP arms in 84%/70% of pts aged ≤60 y and 88%/80% of pts aged >60 y, respectively. Serious TEAEs were observed in 38%/35% of pts aged ≤60 y and 57%/41% of pts aged >60 y, and fatal TEAEs occurred in 4%/2% of pts aged ≤60 y, and 7%/5% of pts aged >60 y, in the Tafa-Len-R-CHOP and R-CHOP arms, respectively.

Trends in efficacy and safety outcomes between Tafa-Len-R-CHOP and R-CHOP were similar when looking at pts aged <70 y and ≥70 y (data to be presented at the meeting).

Conclusions: Tafa-Len-R-CHOP did not impact delivery of the R-CHOP backbone and demonstrated a favorable risk:benefit profile in pts, irrespective of age. The 37% reduction in risk of progression or death with Tafa-Len-R-CHOP in pts ≤60 y with aggressive disease biology is notable.
John M. Burke, MD: Genentech/Roche - Other (including travel support); Genmab - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); Natera - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Immunome - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); CRISPR Therapeutics - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony)